The present invention relates to a skin care formulation that is suitable for the treatment of cellulite.

Provided in the present invention are a novel pro-insulin aspart structure design and a method for preparing insulin aspart. The main steps comprise designing the pro-insulin aspart sequence, constructing recombinant insulin aspart engineered bacteria, inducing an insulin fusion protein expressed in the form of an inclusion body by means of the engineered bacteria, and obtaining a mature insulin aspart material drug by means of denaturing, renaturing enzymatic digestion, and separation purification, By means of changing the recombinant leading peptide and C-peptice sequences, the invention avoids the dangerous and tedious step of cleavage using cyanogen bromide. The C-peptide is shortened to one amino acid, reducing the quality loss of enzymatic digestion conversion.

The disclosure in some aspects, relates to nucleic acids, compositions and kits useful for gene therapy with reduced immune response to transgene products.

Methods for preparing and purifying viral particles, and compositions and uses comprising the same, are provided.

The present invention relates to a composition with an antioxidant activity, comprising a first dry extract derived from plant cell cultures comprising superoxide dismutase of Sulfolobus solfataricus, a second dry extract derived from plant cell cultures comprising superoxide dismutase of Aeropyrum pernix and a third dry extract derived from plant cell cultures comprising superoxide dismutase from Deinococcus radiodurans, wherein said plant cell cultures are cultures of cells belonging to Solanum lycopersicum species.

The present invention is directed to methods for the treatment or prevention of oxidative stress in a cell, e.g., photoreceptor cell, and methods for the treatment and prevention of disorders associated therewith by the administration of an agent, e.g., a nucleic acid molecule, which increases the expression and/or activity of an antioxidant defense protein.

The invention relates to an oral solution having high SOD enzymatic activity and the preparation method therefor, wherein the method comprises: pressing edible plant raw materials, followed by removing large particles by means of centrifugation (1000-4000 rpm, 0-30 min); subsequently, separating the supernatant using two processes of ultrafiltration (the first separation adopting a tubular membrane with pore size ranging from 60-120 kD; the second accomplished by an spiral-wound membrane with pore size ranging from 8-30 kD), before treated using ultra-high pressure at 200-600 MPa for a period of 1-20 min. After treated by the method of the invention, SOD has been activated with enhanced enzymatic activity up to above 10000 U/ml, which has addressed problems related to low enzymatic activity of SOD in products. The products obtained by the present method are more beneficial to human health.

The invention relates to inhibitory nucleic acids and rAAV-based compositions, methods and kits useful for treating Amyotrophic Lateral Sclerosis.

A human platelet lysate preparation that contains human plasma is provided. This preparation can be generated from human platelets by concentrating and washing them under defined conditions to control the degree of human plasma present. The washed platelet concentrate is then subjected to a freeze-thaw cycle to produce platelet lysate which is centrifuged and filtered through 0.65μ, 0.45μ and 0.2μ filters, aliquoted and stored frozen at <−20° C. until thawed for use. This invention describes the novel finding that the controlled addition of human plasma to the lysate preparation significantly enhances the cell growth potency of the lysate preparation. This lysate can be used as a media supplement to replace fetal bovine serum (FBS) or other non-human serum additives used for the culture of mammalian cells. This invention also describes the formulation and use of the lysate preparation as a topical application for skin care, and wound healing, including anti-wrinkling, anti-scarring and wound resolution applications of the invention.

The present invention relates, in part, to methods of preventing or treating macular degeneration in a subject by administering a composition comprising a superoxide dismutase enzyme. The present invention also provides pharmaceutical and/or food compositions comprising a superoxide dismutase enzyme.